Clinical Infectious Diseases · 2005 · 441 citations · 39 references
MedicineInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyInfectious Disease PharmacotherapyPediatric Infectious DiseasesAntiparasitic AgentsAntiparasitic PharmacologyAntiparasitic PharmacotherapyAntiparasitic TherapyInfectious DiarrheaProtozoal InfectionsCryptosporidiosis TreatmentGiardiasis TreatmentGiardicidal AgentsIntestinal Drug-drug InteractionsIntestinal Parasitic Infections In ChildrenIntestinal Parasitic Infections In Immunocompromised HostsProtozoal Intestinal InfectionsProtozoal Treatment
Nitazoxanide is a well‑tolerated, orally administered thiazolide with broad in vitro activity against protozoa and helminths and no known drug‑drug interactions. It is licensed for treating Giardia intestinalis–induced diarrhea in patients ≥1 year and Cryptosporidium‑induced diarrhea in children 1–11, and is an important addition to the antiparasitic arsenal.
Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects. At present, there are no documented drug-drug interactions. Nitazoxanide has been licensed for the treatment of Giardia intestinalis-induced diarrhea in patients >or=1 year of age and Cryptosporidum-induced diarrhea in children aged 1-11 years. At present, it is pending licensure for treatment of infection due to Cryptosporidium species in adults and for use in treating immunocompromised hosts. It represents an important addition to the antiparasitic arsenal.
39
Jean-François Rossignol, Ayman Ayoub, Marc S. Ayers · The Journal of Infectious Diseases · 2001 · 359 citations
Jean‐François Rossignol, H Hidalgo, M. Feregrino et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 1998 · 175 citations